Predicting chemotherapy response to paclitaxel-based therapy in advanced non-small-cell lung cancer with P-glycoprotein expression

Respiration

Volumn 70, Issue 1, 2003, Pages 32-35

  Yeh, J J ^a   Hsu, W H ^b   Wang, J J ^c   Ho, S T ^d   Kao, Albert ^b  

^a PINGTUNG CHRISTIAN HOSPITAL   (Taiwan)

^b CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^c CHI MEI MEDICAL CENTER   (Taiwan)

^d NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

Author keywords

Chemotherapy; Non small cell lung cancer; P glycoprotein

Indexed keywords

CISPLATIN; GLYCOPROTEIN P; PACLITAXEL;

ADULT; AGE; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER TISSUE; CELL TYPE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIOLOGY; SEX; TREATMENT PLANNING; TUMOR CELL; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CARCINOMA, NON-SMALL-CELL LUNG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; NEOPLASM STAGING; P-GLYCOPROTEIN; PACLITAXEL; PREDICTIVE VALUE OF TESTS;

EID: 0037282898     PISSN: 00257931     EISSN: None     Source Type: Journal    
DOI: 10.1159/000068411     Document Type: Article

References (21)

1. Smit EF, Postmus PE: Chemotherapy of non-small cell lung cancer; in Carney DN (ed): Lung Cancer. Avon, Bath Press, 1995, pp 156-172.
2. Alberola V, Rosell R, Gonzalez-Larriba JL, Molina F, Ayala F, Garcia-Conde J, Benito D, Perez JM: Single agent Taxol, 3-hour infusion, in untreated advanced non-small-cell lung cancer. Ann Oncol 1995;6:49S-52S.
3. Francis PA, Kris MG, Rigas JR, Grant SC, Miller VA: Paclitaxel (Taxol) and docetaxel (Taxotere): Active chemotherapeutic agents in lung cancer. Lung Cancer 1995;12(suppl 1):163S-172S.
4. Oka M, Fukuda M, Sakamoto A, Takatani H, Fukuda M, Soda H, Kohno S: The clinical role of MDR1 gene expression in human lung cancer. Anticancer Res 1997;17:721-724.
5. Beck W, Dalton WS: Mechanisms of drug resistance; in DeVita VT, Hellman S Jr, Rosenberg SA (eds): Cancer: Principles and Practice of Oncology, ed 5. Philadelphia, Lippincott, 1997, pp 498-512.
6. Hsu JW, Hsu JY, Chiang CD: Preliminary result of phase II study of paclitaxel and cisplatin chemotherapy for advanced non-small-cell lung cancer in Chinese patients. Am J Clin Oncol 1998;21:487-490.
7. Oken MM, Creech RH, Tormey DC: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982;5:649-655.
8. Kostakoglu L, Kiratli P, Ruacan S, Hayran M, Emri S, Ergun EL, Bekdik CF: Association of tumor washout rates and accumulation of technetium-99m-MIBI with expression of P-glycoprotein in lung cancer. J Nucl Med 1998;39:228-234.
9. Kreisholt J, Sorensen M, Jensen PB, Nielsen BS, Andersen CB, Sehested M: Immunohistochemical detection of DNA topoisomerases IIα, P-glycoprotein and multidrug resistance protein (MRP) in small-cell and non-small-cell lung cancer. Br J Cancer 1998;77:1469-1473.
10. Goldstein LJ, Galski H, Fojo A, Willingham M, Lai SL, Gazdar A, Pirker R, Green A, Crist W, Brodeur GM: Expression of a multidrug-resistance gene in human cancer. J Natl Cancer Inst 1989;81:116-124.
11. Bourhis J, Goldstein LJ, Riou G, Pastan I, Gottesman MM, Benard J: Expression of a human multidrug resistance gene in ovarian carcinomas. Cancer Res 1989;49:5062-5065.
12. Dalton WS, Grogan TM, Meltzer PS, Scheper RJ, Durie BG, Taylor CW, Miller TP, Salmon SE: Drug-resistance in multiple myeloma and non-Hodgkin's lymphoma: Detection of P-glycoprotein and potential circumvention by addition of verapamil to chemotherapy. J Clin Oncol 1989;7:415-424.
13. Zijlstra JG, de Vires EGE, Mulder NH: Multi-factorial drug resistance in an adriamycin-resistance human small cell lung carcinoma cell line. Cancer Res 1987;47:1780-1784.
14. Ueda K, Cornwell MM, Gottesman MM, Pastan I, Roninson IB, Ling V, Riordan JR: The mdr1 gene, responsible for multi-drug resistance, codes for P-glycoprotein. Biochem Biophys Res Commun 1986;141:956-962.
15. Callen DF, Baker E, Simmers RN, Seshadri R, Roninson IB: Localization of the human multi drug resistance gene, MDR1, to 7q21.1. Hum Genet 1987;77:142-144.
16. Gros P, Croop J, Housman D: Mammalian multidrug resistance gene: Complete cDNA sequence indicates strong homology to bacterial transport protein. Cell 1986;47:371-380.
17. Higgins CF: ABC transporters: From microorganisms to man. Annu Rev Cell Biol 1992;8:67-113.
18. van Ark-Otte J, Samelis G, Rubio G, Lopez Saez JB, Pinedo HM, Giaccone G: Effects of tubulin-inhibiting agents in human lung and breast cancer cell lines with different multidrug resistance phenotypes. Oncol Rep 1998;5:249-255.
19. Horwitz SB, Cohen D, Rao S, Ringel I, Shen HJ, Yang CP: Taxol: Mechanism of action and resistance. J Natl Cancer Inst Monogr 1993;15:55-61.
20. Haber M, Burkhart CA, Regl DL, Madafiglio J, Norris MD, Horwitz SB: Altered expression of M β2, the class IIβ-tubulin isotype, in a murine J774.2 cell line with a high level of taxol resistance. J Biol Chem 1995;270:31269-31275.
21. Bhalla K, Huang Y, Tang C, Self S, Ray S, Mahoney ME, Ponnathpur V, Tourkina E, Ibrado AM, Bullock G: Characterization of a human myeloid leukemia cell line highly resistant to taxol. Leukemia 1994;8:465-475.